NASDAQ:THORSynthorx Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Synthorx Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $67.99 0.00 (0.00 %) (As of 01/23/2020) Add Compare Share Today's Range$67.99Now: $67.99▼$67.9950-Day Range$67.99MA: $67.99▼$67.9952-Week Range$11.05Now: $67.99▼$71.90VolumeN/AAverage Volume474,507 shsMarket Capitalization$2.20 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.Read More Beat the Market (BTM) Rank™ 1.1 Analyst's Opinion Consensus RatingSynthorx has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.25, Synthorx has a potential downside of 26.1% from its current price of $67.99.Amount of Analyst CoverageSynthorx has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesSynthorx has received 410 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSynthorx has received 446 “underperform” votes. (Add your “underperform” vote.)Community SentimentSynthorx has received 52.10% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Synthorx and other stocks. Vote “Outperform” if you believe THOR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe THOR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSynthorx does not currently pay a dividend.Dividend GrowthSynthorx does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Synthorx insiders have not sold or bought any company stock.Percentage Held by Insiders53.20% of the stock of Synthorx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.12% of the stock of Synthorx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Synthorx are expected to decrease in the coming year, from ($1.54) to ($2.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Synthorx is -16.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Synthorx is -16.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSynthorx has a P/B Ratio of 10.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.1Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.11 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:THOR Previous Symbol CUSIP88517530 CIK350907 Webwww.synthorx.com Phone858-750-4700Debt Debt-to-Equity RatioN/A Current Ratio18.87 Quick Ratio18.87Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.72 per share Price / Book10.12Profitability EPS (Most Recent Fiscal Year)($6.59) Net Income$-56,610,000.00 Net MarginsN/A Return on Equity-26.09% Return on Assets-24.62%Miscellaneous Employees39 Outstanding Shares32,338,000Market Cap$2.20 billion Next Earnings DateN/A OptionableNot Optionable Receive THOR News and Ratings via Email Sign-up to receive the latest news and ratings for THOR and its competitors with MarketBeat's FREE daily newsletter. Synthorx (NASDAQ:THOR) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Synthorx? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthorx in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Synthorx. How were Synthorx's earnings last quarter? Synthorx Inc (NASDAQ:THOR) released its earnings results on Tuesday, November, 5th. The medical instruments supplier reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.12. View Synthorx's earnings history. What price target have analysts set for THOR? 4 equities research analysts have issued twelve-month price objectives for Synthorx's stock. Their forecasts range from $30.00 to $68.00. On average, they anticipate Synthorx's stock price to reach $50.25 in the next twelve months. This suggests that the stock has a possible downside of 26.1%. View analysts' price targets for Synthorx. Has Synthorx been receiving favorable news coverage? Press coverage about THOR stock has trended somewhat positive on Saturday, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Synthorx earned a news impact score of 0.7 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutSynthorx. Who are some of Synthorx's key competitors? Some companies that are related to Synthorx include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Masimo (MASI). View all competitors. What other stocks do shareholders of Synthorx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synthorx investors own include Pfizer (PFE), Editas Medicine (EDIT), Gilead Sciences (GILD), NVIDIA (NVDA), EXACT Sciences (EXAS), Heron Therapeutics (HRTX), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Advanced Micro Devices (AMD) and salesforce.com (CRM). Who are Synthorx's key executives? Synthorx's management team includes the following people: Dr. Laura K. Shawver, CEO, Pres & Director (Age 61)Dr. Floyd E. Romesberg, Scientific Founder & Director (Age 53)Dr. Marcos Milla Ph.D., Chief Scientific Officer (Age 56)Dr. Joseph Leveque, Chief Medical Officer (Age 58)Terry L. Button, VP & Director When did Synthorx IPO? (THOR) raised $100 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 9,100,000 shares at $10.00-$12.00 per share. Jefferies, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. What is Synthorx's stock symbol? Synthorx trades on the NASDAQ under the ticker symbol "THOR." What is Synthorx's stock price today? One share of THOR stock can currently be purchased for approximately $67.99. How big of a company is Synthorx? Synthorx has a market capitalization of $2.20 billion. The medical instruments supplier earns $-56,610,000.00 in net income (profit) each year or ($6.59) on an earnings per share basis. Synthorx employs 39 workers across the globe. What is Synthorx's official website? The official website for Synthorx is www.synthorx.com. How can I contact Synthorx? Synthorx's mailing address is 11099 North Torrey Pines Road Suite 190, La Jolla CA, 92037. The medical instruments supplier can be reached via phone at 858-750-4700 or via email at [email protected] This page was last updated on 6/6/2020 by MarketBeat.com Staff
